Corvus Pharmaceuticals, Inc. — Director's Dealing 2016

Mar 30, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Corvus Pharmaceuticals, Inc. (CRVS)
CIK: 0001626971
Period of Report: 2016-03-29

Reporting Person: Novo A/S (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-03-29	Common Stock	C	2130492	—	Acquired	2130492	Direct
2016-03-29	Common Stock	C	356888	—	Acquired	2487380	Direct
2016-03-29	Common Stock	P	666666	$15.00	Acquired	3154046	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-03-29	Series A Preferred Stock	$	C	2130492	Disposed		Common Stock (2130492)	Direct
2016-03-29	Series B Preferred Stock	$	C	356888	Disposed		Common Stock (356888)	Direct

Footnotes

F1: The Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") had no expiration date. Upon the closing of the Issuer's initial public offering, the Preferred Stock automatically converted on a one-for-one basis for no additional consideration into common stock.

F2: Represents a purchase from the underwriters in the Issuer's public offering.